Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response
Autore:
Labelle, A; Light, M; Dunbar, F;
Indirizzi:
Royal Ottawa Hosp, Schizophrenia Program, Ottawa, ON K1Z 7K4, Canada RoyalOttawa Hosp Ottawa ON Canada K1Z 7K4 am, Ottawa, ON K1Z 7K4, Canada Janssen Ortho Inc, Clin Res, Toronto, ON, Canada Janssen Ortho Inc Toronto ON Canada o Inc, Clin Res, Toronto, ON, Canada
Titolo Testata:
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
fascicolo: 6, volume: 46, anno: 2001,
pagine: 534 - 541
SICI:
0706-7437(200108)46:6<534:RTOOWS>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
GENDER DIFFERENCES; DOUBLE-BLIND; NEUROLEPTIC TREATMENT; MULTICENTER; HALOPERIDOL; AFTERCARE; DRUG; SOCIOTHERAPY; SCALE; MULTI;
Keywords:
risperidone; schizophrenia; gender; sex; antipsychotics; serotonin; dopamine; extrapyramidal symptoms;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Labelle, A Royal Ottawa Hosp, Schizophrenia Program, 1145 Carling Ave, Ottawa, ON K1Z7K4, Canada Royal Ottawa Hosp 1145 Carling Ave Ottawa ON Canada K1Z 7K4 ada
Citazione:
A. Labelle et al., "Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response", CAN J PSY, 46(6), 2001, pp. 534-541

Abstract

Objective: Given the renewed interest in the role of sex differences in schizophrenia, we undertook a post hoe analysis to determine whether sex differences in treatment response were present among outpatients with schizophrenia who received risperidone in an 8-week, open-label, Phase IV clinical Study. Method. We evaluated 330 adult patients (232 men, 98 women) with a DSM-III-R diagnosis of schizophrenia for safety and 292 (206 men, 86 women) for efficacy. Antipsychotic and antiparkinsonian medications were discontinued atstudy entry. Treatment with risperidone was initiated at a dosage of 2 mg daily, increased to the target dosage of 6 mg daily by day 3, and maintained at 6 mg daily until day 14. The dosage was then maintained at 6 mg daily,increased or decreased by 2 mg daily each week, based on the patient's response. Risperidone treatment was given for 8 weeks; the permitted dosage range was 4 mg to 10 mg daily. Results: Both male and female participants responded well to risperidone treatment; by the final assessment day, they had experienced decreases from baseline in their total Positive and Negative Syndrome Scale (PANSS) scoresof 41.0% and 36.5%, respectively. Most male (77%) and female (78%) participants were considered to be PANSS responders: risperidone was effective against both the positive and negative symptoms of schizophrenia. Both sexes showed improvements over baseline in the incidence and severity of parkinsonism, dystonia, and dyskinesia. No significant (P > 0.05) sex differences intreatment response were observed for any of the efficacy outcomes or in the incidence and severity of extrapyramidal symptoms (EPS). Conclusions: In this population of outpatients with chronic schizophrenia,both men and women responded well to flexible doses of risperidone. Alo significant sex differences were evident either in treatment response or in neurological side effects. The absence of sex differences in response to risperidone treatment may obviate the need for a sex-based differential dosingin schizophrenia management.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:09:14